Andrew Hall
Chief Executive Officer bei IMV INC.
Vermögen: 12 $ am 31.12.2023
Aktive Positionen von Andrew Hall
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| IMV INC. | Director/Board Member | 01.01.2022 | - |
| Chief Executive Officer | 04.08.2021 | - | |
| Corporate Officer/Principal | 10.11.2020 | 04.08.2021 |
Karriereverlauf von Andrew Hall
Ehemalige bekannte Positionen von Andrew Hall
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | - | - |
| CELGENE | Corporate Officer/Principal | - | - |
Ausbildung von Andrew Hall
| University of Melbourne | Undergraduate Degree |
| RMIT University | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| Australien | 3 |
| Kanada | 2 |
Operativ
| Corporate Officer/Principal | 3 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| IMV INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Börse
- Insiders
- Andrew Hall
- Erfahrung
